



Press Release

Following Success of Pilot, Cenix BioScience and Schering AG enter into Agreement on Multiple RNAi-based Target Validation Projects

Dresden, Germany, October 25, 2005 – Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that following the success of a pilot project started in late 2004, it has entered into a new agreement with Schering AG to extend their target validation partnership.

Started in late 2004, the pilot project focused on the application of Cenix' combination of high throughput (HT) RNAi technology with multiplexed, high content (HC) phenotypic analyses to efficiently generate detailed *in vitro* validation data for over 100 target candidates in multiple mammalian cell types. Having now completed this initial project and achieved all required performance milestones, Cenix has clearly demonstrated its ability to enhance and accelerate efforts towards prioritizing targets for further internal development.

As a result of this success, the two companies have now entered into a new agreement, setting the terms under which Schering will outsource up to 6 more projects of similar type, i.e. mandating Cenix to carry out HT-RNAi validation programs in human cells to rapidly and efficiently screen through large collections of target candidate genes previously identified by Schering.

"Though quite challenging, the first target validation project with Schering was scientifically very gratifying and the overall interaction has been a true pleasure for our team" said Dr. Christophe Echeverri, CEO/CSO of Cenix BioScience. "We are excited by the prospect of continuing this work and look forward to further contributing to such an excellent program."

No financial terms were disclosed.

About Cenix BioScience GmbH

Cenix BioScience GmbH is a pioneer and leader in high throughput (HT), genome-driven applications of RNA interference (RNAi) for the discovery and validation of new therapeutic drug targets. Founded in 1999 as the first biotechnology company specializing exclusively in HT-RNAi, Cenix has accumulated unparalleled depth and breadth of experience in this field, combining high content phenotypic analyses with proprietary genome-wide RNAi libraries for use in key experimental systems, including a wide range of human and rodent cells. Cenix is now making its unique expertise accessible to industry and academic researchers through highly customizable research services. For more information about Cenix, please visit the company's website www.cenix-bioscience.com.

For further information please contact:

Cenix BioScience GmbH
Zisi Fotev, Chief Business Officer
Tel: +49 (0) 351 4173 148
Email: fotev@cenix-bioscience.com
Web: www.cenix-bioscience.com